 Antibodies, Monoclonal
"Antibodies, Monoclonal" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Antibodies produced by a single clone of cells.
| Descriptor ID |
D000911
|
| MeSH Number(s) |
D12.776.124.486.485.114.224 D12.776.124.790.651.114.224 D12.776.377.715.548.114.224
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Antibodies, Monoclonal".
Below are MeSH descriptors whose meaning is more specific than "Antibodies, Monoclonal".
This graph shows the total number of publications written about "Antibodies, Monoclonal" by people in this website by year, and whether "Antibodies, Monoclonal" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1981 | 2 | 2 | 4 | | 1982 | 6 | 4 | 10 | | 1983 | 13 | 6 | 19 | | 1984 | 10 | 14 | 24 | | 1985 | 9 | 8 | 17 | | 1986 | 5 | 14 | 19 | | 1987 | 16 | 20 | 36 | | 1988 | 14 | 17 | 31 | | 1989 | 7 | 17 | 24 | | 1990 | 9 | 13 | 22 | | 1991 | 9 | 11 | 20 | | 1992 | 5 | 17 | 22 | | 1993 | 3 | 19 | 22 | | 1994 | 12 | 12 | 24 | | 1995 | 7 | 16 | 23 | | 1996 | 4 | 12 | 16 | | 1997 | 4 | 8 | 12 | | 1998 | 6 | 17 | 23 | | 1999 | 11 | 18 | 29 | | 2000 | 8 | 11 | 19 | | 2001 | 15 | 21 | 36 | | 2002 | 10 | 16 | 26 | | 2003 | 16 | 14 | 30 | | 2004 | 24 | 18 | 42 | | 2005 | 24 | 18 | 42 | | 2006 | 28 | 17 | 45 | | 2007 | 31 | 14 | 45 | | 2008 | 28 | 21 | 49 | | 2009 | 34 | 19 | 53 | | 2010 | 40 | 27 | 67 | | 2011 | 22 | 14 | 36 | | 2012 | 27 | 12 | 39 | | 2013 | 23 | 10 | 33 | | 2014 | 29 | 13 | 42 | | 2015 | 15 | 10 | 25 | | 2016 | 26 | 9 | 35 | | 2017 | 32 | 11 | 43 | | 2018 | 26 | 15 | 41 | | 2019 | 22 | 13 | 35 | | 2020 | 10 | 8 | 18 | | 2021 | 0 | 3 | 3 |
To return to the timeline, click here.
Below are the most recent publications written about "Antibodies, Monoclonal" by people in Profiles.
-
Juloori A, Vokes EE. Beyond PACIFIC: Uncharted Waters. J Thorac Oncol. 2021 05; 16(5):715-718.
-
Bellmunt J, Hussain M, Gschwend JE, Albers P, Oudard S, Castellano D, Daneshmand S, Nishiyama H, Majchrowicz M, Degaonkar V, Shi Y, Mariathasan S, Grivas P, Drakaki A, O'Donnell PH, Rosenberg JE, Geynisman DM, Petrylak DP, Hoffman-Censits J, Bedke J, Kalebasty AR, Zakharia Y, van der Heijden MS, Sternberg CN, Davarpanah NN, Powles T. Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2021 04; 22(4):525-537.
-
Faivre-Finn C, Vicente D, Kurata T, Planchard D, Paz-Ares L, Vansteenkiste JF, Spigel DR, Garassino MC, Reck M, Senan S, Naidoo J, Rimner A, Wu YL, Gray JE, Özgüroglu M, Lee KH, Cho BC, Kato T, de Wit M, Newton M, Wang L, Thiyagarajah P, Antonia SJ. Four-Year Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC-an Update From the PACIFIC Trial. J Thorac Oncol. 2021 05; 16(5):860-867.
-
Goldman JW, Dvorkin M, Chen Y, Reinmuth N, Hotta K, Trukhin D, Statsenko G, Hochmair MJ, Özgüroglu M, Ji JH, Garassino MC, Voitko O, Poltoratskiy A, Ponce S, Verderame F, Havel L, Bondarenko I, Kazarnowicz A, Losonczy G, Conev NV, Armstrong J, Byrne N, Thiyagarajah P, Jiang H, Paz-Ares L. Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2021 01; 22(1):51-65.
-
Augustin M, Lambert J, Zema C, Thompson EHZ, Yang M, Wu EQ, Garcia-Horton V, Geng Z, Valdes JM, Joshi A, Gordon KB. Effect of Risankizumab on Patient-Reported Outcomes in Moderate to Severe Psoriasis: The UltIMMa-1 and UltIMMa-2 Randomized Clinical Trials. JAMA Dermatol. 2020 12 01; 156(12):1344-1353.
-
Kirkpatrick E, Henry C, McMahon M, Jiang K, Strohmeier S, van Bakel H, Wilson PC, Krammer F. Characterization of Novel Cross-Reactive Influenza B Virus Hemagglutinin Head Specific Antibodies That Lack Hemagglutination Inhibition Activity. J Virol. 2020 11 09; 94(23).
-
Guthmiller JJ, Lan LY, Fernández-Quintero ML, Han J, Utset HA, Bitar DJ, Hamel NJ, Stovicek O, Li L, Tepora M, Henry C, Neu KE, Dugan HL, Borowska MT, Chen YQ, Liu STH, Stamper CT, Zheng NY, Huang M, Palm AE, García-Sastre A, Nachbagauer R, Palese P, Coughlan L, Krammer F, Ward AB, Liedl KR, Wilson PC. Polyreactive Broadly Neutralizing B cells Are Selected to Provide Defense against Pandemic Threat Influenza Viruses. Immunity. 2020 12 15; 53(6):1230-1244.e5.
-
Akiyama S, Yamada A, Sakuraba A. Safety of nontumor necrosis factor-targeted biologics in the COVID-19 pandemic. J Med Virol. 2021 02; 93(2):714-716.
-
Chen X, Shi M, Tong X, Kim HK, Wang LX, Schneewind O, Missiakas D. Glycosylation-dependent opsonophagocytic activity of staphylococcal protein A antibodies. Proc Natl Acad Sci U S A. 2020 09 15; 117(37):22992-23000.
-
Voorhees PM, Kaufman JL, Laubach J, Sborov DW, Reeves B, Rodriguez C, Chari A, Silbermann R, Costa LJ, Anderson LD, Nathwani N, Shah N, Efebera YA, Holstein SA, Costello C, Jakubowiak A, Wildes TM, Orlowski RZ, Shain KH, Cowan AJ, Murphy S, Lutska Y, Pei H, Ukropec J, Vermeulen J, de Boer C, Hoehn D, Lin TS, Richardson PG. Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial. Blood. 2020 08 20; 136(8):936-945.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|